LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

Authors :: J. Mazieres
T.M. Kim
B.K. Lim
M. Wislez
C. Dooms
G. Finocchiaro
H. Hayashi
C.K. Liam
J. Raskin
L.M. Tho
F. de Marinis
E. Nadal
E. Smit
X. Le
S. Brutlach
A.M. O'Brate Grupp
S. Adrian
B. Ellers-Lenz
N. Karachaliou
Y-L. Wu
Source :: Annals of Oncology. 33:S1419-S1420
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Full Text Access

Tools